Another setback for AstraZeneca as lupus drug fails phase 3 test

Despite encouraging midstage data for AstraZeneca’s drug for systemic lupus erythematosus (SLE), anifrolumab has missed the target in the first of two ongoing phase 3 trials, putting its future in doubt.